New Targeted Therapies for cancers, autoimmune, fibrotic, and infectious diseases

Speaker: Dr. Philip S. Low

Dr. Low's lab targets drugs specifically directed to pathologic cells to improve the potency of the drug, and to prevent the collateral toxicity that would normally occur if the drug were allowed to enter healthy cells. His program will describe how this is done and how it has dramatically improved the effectiveness of cancer, autoimmune and other diseases.

Dr. Philip S. Low is the Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry at Purdue University. Dr. Low has spent over 45 years designing targeted imaging and therapeutic agents for the diagnosis and treatment of human diseases. He has published >500 scientific articles that have earned an H-index of >125 and has >760 US patents/patents pending. Five drugs stemming from his research are currently undergoing human clinical trials (including a malaria therapy in phase 3), and three of his previous drugs have received FDA approval in the last three years. Low has also founded seven companies (Endocyte Inc., OnTarget Laboratories Inc., Umoja Biopharma, Morphimmune Inc., Novosteo Inc., Eradivir Inc. and ErythroCure Inc.) to commercialize his discoveries.

Sponsored by Judy Weitzman